Abstracts tagged "dermatomyositis"

Abstract Number: 1221 • ACR Convergence 2023
Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)
Albert Chow¹, Sean Koester², Evan Pepper-Tunick³, Peggy Lee⁴, Mary Eckert⁵, Laurie Brenchley⁶, Pamela Gardner⁶, Naisi Li², adam Schiffenbauer⁷, Rita Volochayev⁷, Nastaran Bayat⁸, Jeffrey McLean⁹, Lisa Rider¹⁰, Susan Shenoi¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ³Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, ⁴Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰NIEHS, NIH, Bethesda, MD, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare immune-mediated disease of childhood that is thought to result from genetic predisposition and environmental drivers, with documented links to microbial…
Abstract Number: 1960 • ACR Convergence 2023
From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence
Hao Cheng Shen¹, Victoria Ivensky², Yves Troyanov³, Josiane Bourre-Tessier¹, Farah Zarka², Sabrina Hoa⁴, Jessica Nehme², Jean-Paul Makhzoum⁵, Anne-Marie Mansour², Rosalie-Selene Meunier², Alexandra Mereniuk², Darosa Lim⁶, Jean-Pierre Raynauld¹, Eric Rich¹, Jean-Richard Goulet¹, Marianne Landry⁷, Maude Bouchard-Marmen⁸, Valerie Leclair⁹, Hugues Allard-Chamard¹⁰, Marie Hudson¹¹, Erin O'Ferrall¹², Rami Massie¹², Jason Karamchandani¹³, Benjamin Ellezam¹⁴, Ira N. Targoff¹⁵, Minoru Satoh¹⁶, Marvin Fritzler¹⁷, Jean-Luc Senecal¹, Alain Meyer¹⁸ and Oceane Landon-Cardinal¹, ¹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²Hôpital du Sacré-Coeur de Montréal, Université de Montréal, Montreal, QC, Canada, ³Hôpital du Sacré-Coeur de Montréal, Centre hospitalier de l'Université de Montreal (CHUM), Université de Montréal, Montreal, QC, Canada, ⁴University of Montreal, Brossard, QC, Canada, ⁵Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Hôpital de LaSalle, Montreal, QC, Canada, ⁸CHU de Québec, Université Laval, Quebec City, QC, Canada, ⁹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹⁰Université de Sherbrooke, Sherbrooke, QC, Canada, ¹¹McGill University, Montréal, QC, Canada, ¹²Montreal Neurological Institute, McGill University, Montreal, QC, Canada, ¹³McGill University Health Center (MUHC), McGill University, Montreal, QC, Canada, ¹⁴CHU Sainte-Justine, Université de Montréal, Montreal, QC, Canada, ¹⁵Veteran's Affairs Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: The risk of cancer is increased in patients with pure dermatomyositis (DM), i.e. patients with a DM rash and without an anti-MDA-5 syndrome, a…
Abstract Number: 0337 • ACR Convergence 2023
Impact of Photosensitivity on Quality of Life in Dermatomyositis
Kirubel Gebre¹, Rachita Pandya², Julianne Kleitsch², Darosa Lim³, Rui Feng³ and victoria werth⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Lancaster, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania, Wynnewood, PA
Background/Purpose: Photosensitivity (PS) has been documented in dermatomyositis (DM) with symptoms including aggravation of preexisting cutaneous lesions and abnormal transient erythemal responses (Cheong WK et…
Abstract Number: 1222 • ACR Convergence 2023
The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM)
Albert Chow¹, Hyun Song², Laurie Brenchley³, Nastaran Bayat⁴, Mary Eckert⁵, Sean Koester⁶, adam Schiffenbauer⁷, Rita Volochayev⁷, Pamela Gardner³, Peggy Lee⁸, Jeffrey McLean⁹, Susan Shenoi¹⁰, Lisa Rider¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Department of Dentistry, Seattle Children's Hospital, Seattle, WA, ³Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁴Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰Seattle Childrens Hospital, Mercer Island, WA, ¹¹NIEHS, NIH, Bethesda, MD, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare vasculopathy of unknown etiology characterized by typical rashes and proximal weakness. JDM has been associated with gingivitis, which can be…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 0748 • ACR Convergence 2023
Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT
Kastriot Kastrati¹, Thomas S Nakuz², Oana C Kulterer², Stephan Blüml³, Michael Bonelli³, Irina Gessl⁴, Hans-Peter Kiener³, Werner Langsteger², Daniel Mrak³, Florian Prayer⁵, Helmut Prosch⁵, Elisabeth Simader³, Tatjana Traub-Weidinger², Daniel Aletaha⁶, Helga Radner⁷, Marcus Hacker² and Peter Mandl³, ¹Dept of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna (Austria), Vienna, Austria, ²Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of idiopathic inflammatory myopathies (IIM) ranging up to 78% in IIM and is a key contributor…
Abstract Number: 1230 • ACR Convergence 2023
Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive
Nicholas McClellan, Sarah Vandenbergen, Sophia Matossian, J. Michelle Kahlenberg and Jessica Turnier, University of Michigan, Ann Arbor, MI
Background/Purpose: Juvenile dermatomyositis (JDM) is characterized by multiorgan vasculopathy, and degree of vasculopathy can indicate more severe disease. Nailfold capillaroscopy is a non-invasive method to…
Abstract Number: 1964 • ACR Convergence 2023
Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
Jacob Colello¹, Kirsten Riggle¹, Galen Foulke², Peri Newman¹, Jamie Carter¹ and Nancy Olsen¹, ¹TE-Penn State MS Hershey Medical Center, Hershey, PA, ²Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is a relatively rare condition with significant morbidity and mortality across the lifespan.Recent advances in diagnostics and therapeutics have significant potential to…
Abstract Number: 0825 • ACR Convergence 2023
A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS)
Rachita Pandya¹, Joshua Dan², Julianne Kleitsch¹, Darosa Lim³, Barbara White⁴ and Victoria P. Werth⁵, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³University of Pennsylvania, Philadelphia, PA, ⁴SFJ Pharmaceuticals, Towson, MD, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Current clinical trials in dermatomyositis (DM) are largely focused on muscle improvement, and use the Total Improvement Score (TIS) as the primary efficacy measure.…
Abstract Number: 1236 • ACR Convergence 2023
Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort
Dawn Gist¹, Sarah Molina², Maria Pereira³, Andrea Ramirez³, Cagri Yildirim-Toruner⁴ and Marietta De Guzman³, ¹Baylor College of Medicine Pediatrics Residency, Houston, TX, ²Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is an idiopathic inflammatory myopathy that causes muscle weakness, rash, vascular changes, or other organ involvement. The phenotypes may vary, and…
Abstract Number: 1972 • ACR Convergence 2023
Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Christina Charles-Schoeman¹, Joachim Schessl², Rohit Aggarwal³ and and the ProDERM investigators⁴, ¹UCLA Medical Center, Santa Monica, CA, ²Friedrich-Baur-Institute, Ludwig-Maximilians University of Munich, Munich, Germany, ³University of Pittsburgh, Pittsburgh, PA, ⁴Institutions in Europe and North America, Vienna, Austria
Background/Purpose: Dermatomyositis (DM) is an immune-mediated inflammatory myopathy (IIM). Two subsets ofautoantibodies have been identified in patients with IIM: Myositis-specific antibodies (MSA) and myositis-associated antibodies…
Abstract Number: 1022 • ACR Convergence 2023
Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023)
Joseph Fares¹, ross Summer¹ and Giorgos Loizidis², ¹The Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University Hospital, Philadelphia, PA, ²Division of Rheumatology, Thomas Jefferson University Hospital, Philadelphia, PA
Background/Purpose: Despite the proven cardioprotective benefits of statin therapy in RA, concern for statin-associated muscle symptoms (SAMS) might deter clinicians from prescribing them to DM/PM…
Abstract Number: 1249 • ACR Convergence 2023
Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis
Kaveh Ardalan¹, Angel Davalos¹, Hwanhee Hong¹, Bryce Reeve¹, Christoph Hornik¹, M. Anthony Moody¹, Donald Lloyd-Jones², Eveline Wu³, Audrey Ward¹, Rebecca Sadun⁴, Jeffrey Dvergsten⁵, Ann Reed⁶, Mark Connelly⁷ and Laura Schanberg¹, ¹Duke University School of Medicine, Durham, NC, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³University of North Carolina School of Medicine, Chapel Hill, NC, ⁴Duke University, Durham, NC, ⁵Duke University School of Medicine, Hillsborough, NC, ⁶Duke University School of Medicine, Chapel HIll, NC, ⁷Children's Mercy Kansas City / University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Juvenile lupus (JSLE) and dermatomyositis (JDM) patients are at high risk for cardiovascular disease (CVD). The American Heart Association cardiovascular health (CVH) construct is…
Abstract Number: 2037 • ACR Convergence 2023
Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology
COMFORT ANIM-KORANTENG¹, YONG EUN², Okeoghene Akpoigbe² and AMANDA SAMMUT², ¹Harlem Hospital Center, New York, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Many studies have shown that rheumatologic conditions are associated with a higher risk of depression. The two most common methods to detect depression in…
Abstract Number: 1053 • ACR Convergence 2023
Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease
Denis Krutko¹, Selene Rubino¹, Brian Sauer², Jorge Rojas Jr³, Gary Kunkel¹, Jessica A Walsh⁴, Shardool Patel⁵, Grant Cannon⁶ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City VA/University of Utah, Salt Lake City, UT, ³Puget Sound VA and University of Utah, Seattle, WA, ⁴Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Data on Immune Checkpoint inhibitor (ICI) use in patients with previously diagnosed inflammatory muscle disease (IMD) is limited as these patients were excluded from…

« Previous Page
1
…
5
6
7
8
9
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].